Skip to main content
About us
Who We Are
Leadership Team
Board of Directors
Advisory Board
AI platform technologies
Pipeline
Overview
EVX-01 clinical trial
Investors
Overview
Evaxion Shares
Share Data
Share Charts
Historical Lookup
Investment Calculator
Analyst Coverage
Reports & Presentations
Quarterly Reports
Annual Reports
SEC Filings
Financial Calendar
Presentations
Corporate Governance
Governance Documents
Committees
Annual Shareholder Meeting
Resources
Investor FAQs
News & Events
Press Releases
Events
Stay in Touch
Careers
Contact
Information Request Form
Contact us
Site Search
open mobile navigation
Press Releases
close mobile navigation
About us
Who We Are
Leadership Team
Board of Directors
Advisory Board
AI platform technologies
Pipeline
Overview
EVX-01 clinical trial
Investors
Overview
Evaxion Shares
Share Data
Share Charts
Historical Lookup
Investment Calculator
Analyst Coverage
Reports & Presentations
Quarterly Reports
Annual Reports
SEC Filings
Financial Calendar
Presentations
Corporate Governance
Governance Documents
Committees
Annual Shareholder Meeting
Resources
Investor FAQs
News & Events
Press Releases
Events
Stay in Touch
Careers
Contact
Information Request Form
Contact us
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
01/18/2022
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma